Addex Therapeutics Ltd.
For the period ended Jun 25, 2026. Filed Jun 25, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 25, 2026 · Filed Jun 25, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · 5. Segment reporting
5. Segment reporting
Management has identified one single operating segment, related to the discovery, development and commercialization of small-molecule pharmaceutical products.
Information about products, services and major customers
External income of the Group is derived from the business of discovery, development and commercialization of pharmaceutical products. Income primarily relates to research services provided to a pharmaceutical company and the fair value of services received from Neurosterix’s Group at zero cost.
Information about geographical areas
External income is exclusively recorded in the Swiss operating company.
Analysis of revenue from contract with customer and other income by nature is detailed as follows:
| For the three months ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Fair value of services received at zero cost from Neurosterix’s Group | 7,691 | 71,055 |
| Total | 7,691 | 71,055 |
For more detail, refer to note 17 “Other income”.
The geographical allocation of long-lived assets is detailed as follows:
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Switzerland | 3,569,222 | 4,683,813 |
| France | 332 | 335 |
| Total | 3,569,554 | 4,684,148 |
The geographical analysis of operating costs is as follows:
| For the three months ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Switzerland | 484,344 | 673,848 |
| United States of America | 1,993 | 2,315 |
| France | 1,181 | 1,154 |
| Total operating costs (note 18) | 487,518 | 677,317 |
The capital expenditure during the three-month periods ended March 31, 2025 and 2026 is nil.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.